Differential activation of mitogen-activated protein kinases in ischemic and nitroglycerin-induced preconditioning

Basic Research in Cardiology
E K IliodromitisD T Kremastinos

Abstract

Previous studies have shown that the cardioprotective effect of ischemic preconditioning (IPC) can be mimicked pharmacologically with clinically relevant agents, including nitric oxide (NO) donors. However, whether pharmacological preconditioning shares the same molecular mechanism with IPC is not fully elucidated. The present study aimed to determine the activation of mitogen-activated protein kinases (MAPKs) (ERK1/2, p38 MAPK and p46/p54 JNKs) during ischemia and at reperfusion in nitroglycerin-induced preconditioning as compared to IPC and to correlate this with the conferred cardioprotection in anesthetized rabbits. Sixty minutes of intravenous administration of nitroglycerin was capable of inducing both early and late phase preconditioning in anesthetized rabbits, as it was expressed by the reduction of infarct size. Despite the cardioprotective effect conferred by both ischemic and nitroglycerin-induced preconditioning, there was a differential phosphorylation of MAPKs between the studied groups. p38 MAPK was activated early in ischemia in both ischemic and the early nitroglycerin-induced preconditioning while JNKs were markedly increased only after IPC. Furthermore, in these groups, ERK1/2 were activated during reperfusi...Continue Reading

References

Dec 2, 1998·Basic Research in Cardiology·R BolliJ Zhang
Apr 25, 2000·Journal of Molecular and Cellular Cardiology·H PostG Heusch
Jun 9, 2000·Annual Review of Physiology·M V CohenJ M Downey
Apr 4, 2001·Naunyn-Schmiedeberg's Archives of Pharmacology·M C MichelG Heusch
May 1, 2001·Basic Research in Cardiology·R M FryerG J Gross
Aug 24, 2001·Basic Research in Cardiology·G F Baxter, P Ferdinandy
Oct 31, 2001·Cardiovascular Research·R SchulzG Heusch
Mar 22, 2002·Clinical and Experimental Pharmacology & Physiology·E VasaraA Lazou
Mar 29, 2002·Naunyn-Schmiedeberg's Archives of Pharmacology·Zhi-Hong ZhouYuan-Jian Li
Sep 18, 2002·Journal of Molecular and Cellular Cardiology·E K IliodromitisD Th Kremastinos
Apr 10, 2003·British Journal of Pharmacology·Efstathios K IliodromitisDimitrios Th Kremastinos
May 22, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Rainer SchulzGerd Heusch
Aug 14, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Garrett J Gross, Jason N Peart
Sep 25, 2003·Physiological Reviews·Derek M Yellon, James M Downey
Mar 27, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Qining QinJames M Downey
Apr 19, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Robert D LasleyRobert M Mentzer
May 27, 2005·American Journal of Physiology. Cell Physiology·Ida Najwer, Brenda Lilly

❮ Previous
Next ❯

Citations

Jan 12, 2011·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Yong ZhangHongli Shan
Jun 15, 2011·European Journal of Pharmacology·Thomais MarkouAntigone Lazou
Mar 11, 2008·Bioorganic & Medicinal Chemistry·Theano FotopoulouDimitrios Th Kremastinos
Nov 23, 2007·European Journal of Pharmacology·Efstathios K IliodromitisDimitrios Th Kremastinos
May 9, 2009·British Journal of Pharmacology·S K WalshC L Wainwright
Mar 31, 2015·Journal of Cardiovascular Pharmacology and Therapeutics·André LuzSevero Torres
Mar 29, 2014·Experimental Biology and Medicine·Claudia PennaPasquale Pagliaro
May 13, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Rosa MazzaSushil K Mahata
Aug 4, 2009·The Journal of Experimental Biology·Amal Idris Malik, Kenneth B Storey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.